GlaxoSmithKline completes VRS scheme as part of its business review

GlaxoSmithKline Pharmaceuticals has completed its voluntary retirement scheme (VRS) for certain employees in the commercial function (field sales and head office) as part of its ongoing strategic review and transformation initiatives. The company has incurred a one-time cost of Rs 156.57 crore for the VRS, it said in a regulatory filing on Thursday.

The company revealed last month that its board, as part of a strategic business review,…